nach oben

Current HIV/AIDS Reports

Erschienen in:

01.09.2013 | Metabolic Complications and Comorbidity (JM Kilby, Section Editor)

Non-AIDS-defining Cancers Among HIV-Infected Patients

verfasst von: James Cutrell, Roger Bedimo

Erschienen in: Current HIV/AIDS Reports | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

In the highly active antiretroviral therapy (HAART) era, the incidence of non-AIDS-defining cancers (NADC) has increased and contributes to a growing proportion of mortality in the aging HIV-infected population. The underlying pathogenic mechanisms of increased cancer risk are incompletely understood. Potential contributors include oncogenic effects of the HIV virus, immunosuppression, chronic inflammation and immune activation, exposure to HAART, higher rates of oncogenic viral coinfections and traditional cancer risk factors. HIV-infected patients often present with NADC at younger ages with more aggressive or advanced stage disease. However, when standard cancer therapy is given, treatment outcomes appear similar to the non-HIV population. These facts highlight the importance of clinicians’ maintaining a high index of suspicion, performing age-appropriate screening, and optimizing cancer therapy. Development of novel strategies for screening, prevention, and treatment of NADC will be required to reverse these epidemiologic trends and improve the survival of HIV-infected patients.

Lewden C, May T, Rosenthal E, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: the “Mortalite 2000 and 2005” surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr. 2008;48:590–8.PubMedCrossRef

Palella Jr FJ, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43:27–34.PubMedCrossRef

Schneider E, Whitmore S, Glynn KM, et al. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years–United States, 2008. MMWR Recomm Rep. 2008;57:1–12.PubMed

•• Shiels MS, Pfeiffer RM, Gail MH, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. 2011;103:753–62. This study provides U.S. national estimates of annual cancer burden by calculating incident cancers, by cancer type, from 1991 to 2005 in HIV-infected patients with and without AIDS. A dramatic shift in the spectrum of cancers from ADC to NADC occurred, driven by aging and growth of the HIV population.PubMedCrossRef

Engels EA, Biggar RJ, Hall HI, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer. 2008;123:187–94.PubMedCrossRef

Deeken JF, Tjen ALA, Rudek MA, et al. The rising challenge of non-AIDS-defining cancers in HIV-infected patients. Clin Infect Dis. 2012;55:1228–35.PubMedCrossRef

• Simard EP, Engels EA. Cancer as a cause of death among people with AIDS in the United States. Clin Infect Dis. 2010;51:957–62. This study described cancer-related mortality in a US registry-based cohort of 83,282 AIDS patients from 1980 to 2006. Significant decreases in mortality from ADC and NADC occurred during the HAART era, but due to faster declines in mortality from other AIDS-related deaths, the proportion of deaths from cancers increased, particularly from NHL and lung cancers.PubMedCrossRef

Bedimo RJ, McGinnis KA, Dunlap M, et al. Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART era: impact of immunosuppression. J Acquir Immune Defic Syndr. 2009;52:203–8.PubMedCrossRef

Shiels MS, Cole SR, Kirk GD, Poole C. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr. 2009;52:611–22.PubMedCrossRef

10.

Engels EA. Non-AIDS-defining malignancies in HIV-infected persons: etiologic puzzles, epidemiologic perils, prevention opportunities. AIDS. 2009;23:875–85.PubMedCrossRef

11.

Silverberg MJ, Chao C, Leyden WA, et al. HIV infection and the risk of cancers with and without a known infectious cause. AIDS. 2009;23:2337–45.PubMedCrossRef

12.

Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med. 2008;148:728–36.PubMedCrossRef

13.

Crum-Cianflone N, Hullsiek KH, Marconi V, et al. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS. 2009;23:41–50.PubMedCrossRef

14.

Powles T, Robinson D, Stebbing J, et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol. 2009;27:884–90.PubMedCrossRef

15.

• Franceschi S, Lise M, Clifford GM, et al. Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. Br J Cancer. 2010;103:416–22. This update from the Swiss HIV Cohort Study reports SIRs and age-standardized cancer incidence comparing 9429 HIV-infected patients to controls from Swiss cantonal cancer registries in the pre-, early-, and late-HAART periods. Increases in the incidence of select NADC occurred in the early-HAART era, but overall NADC incidence was double that of the general population and remained stable in all periods.PubMedCrossRef

16.

• Dubrow R, Silverberg MJ, Park LS, et al. HIV infection, aging, and immune function: implications for cancer risk and prevention. Curr Opin Oncol. 2012;24:506–16. This recent review explores in detail the relationship of immunodeficiency, chronic inflammation, and immune activation to cancer risk in HIV-infected patients. The authors also summarize the existing data regarding the relationship of CD4 count to overall NADC rates and specific cancer types, discussing possible explanations for discrepant findings.PubMedCrossRef

17.

Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med. 2006;145:397–406.PubMedCrossRef

18.

Frisch M, Biggar RJ, Engels EA, Goedert JJ. Association of cancer with AIDS-related immunosuppression in adults. JAMA. 2001;285:1736–45.PubMedCrossRef

19.

Persson EC, Shiels MS, Dawsey SM, et al. Increased risk of stomach and esophageal malignancies in people with AIDS. Gastroenterology. 2012;143:943–50. e942.PubMedCrossRef

20.

Silverberg MJ, Leyden W, Warton EM, et al. HIV infection status, immunodeficiency, and the incidence of non-melanoma skin cancer. J Natl Cancer Inst. 2013;105:350–60.PubMedCrossRef

21.

Burgi A, Brodine S, Wegner S, et al. Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer. 2005;104:1505–11.PubMedCrossRef

22.

Suneja G, Shiels MS, Melville SK, et al. Disparities in the treatment and outcomes of lung cancer among HIV-infected individuals. AIDS. 2013;27:459–68.PubMedCrossRef

23.

Brau N, Fox RK, Xiao P, et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol. 2007;47:527–37.PubMedCrossRef

24.

Goedert JJ, Schairer C, McNeel TS, et al. Risk of breast, ovary, and uterine corpus cancers among 85,268 women with AIDS. Br J Cancer. 2006;95:642–8.PubMedCrossRef

25.

Levine AM, Seaberg EC, Hessol NA, et al. HIV as a risk factor for lung cancer in women: data from the Women’s Interagency HIV Study. J Clin Oncol. 2010;28:1514–9.PubMedCrossRef

26.

Silverberg MJ, Lau B, Justice AC, et al. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis. 2012;54:1026–34.PubMedCrossRef

27.

Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005;97:425–32.PubMedCrossRef

28.

Mbulaiteye SM, Biggar RJ, Goedert JJ, Engels EA. Immune deficiency and risk for malignancy among persons with AIDS. J Acquir Immune Defic Syndr. 2003;32:527–33.PubMedCrossRef

29.

Bruyand M, Thiebaut R, Lawson-Ayayi S, et al. Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort. Clin Infect Dis. 2009;49:1109–16.PubMedCrossRef

30.

Guiguet M, Boue F, Cadranel J, et al. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol. 2009;10:1152–9.PubMedCrossRef

31.

Prosperi MC, Cozzi-Lepri A, Castagna A, et al. Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study. Clin Infect Dis. 2010;50:1316–21.PubMedCrossRef

32.

Reekie J, Kosa C, Engsig F, et al. Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies. Cancer. 2010;116:5306–15.PubMedCrossRef

33.

Kesselring A, Gras L, Smit C, et al. Immunodeficiency as a risk factor for non-AIDS-defining malignancies in HIV-1-infected patients receiving combination antiretroviral therapy. Clin Infect Dis. 2011;52:1458–65.PubMedCrossRef

34.

Krishnan S, Schouten JT, Jacobson DL, et al. Incidence of non-AIDS-defining cancer in antiretroviral treatment-naive subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis. Oncology. 2011;80:42–9.PubMedCrossRef

35.

Bedimo R, Chen RY, Accortt NA, et al. Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989–2002. Clin Infect Dis. 2004;39:1380–4.PubMedCrossRef

36.

Monforte A, Abrams D, Pradier C, et al. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS. 2008;22:2143–53.PubMedCrossRef

37.

•• Silverberg MJ, Chao C, Leyden WA, et al. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev. 2011;20:2551–9. This study from the Kaiser Permanente HIV cohort compared cancer risk in 20,775 HIV-infected patients and 215,158 HIV-infected controls from the same healthcare system. After adjustment for demographic and traditional cancer risk factors, elevated RRs were seen for 7 of 10 cancer types studied and an association of lower CD4 count, and elevated risk was seen for 9 of 10 cancer types studied.PubMedCrossRef

38.

Harrod R, Nacsa J, Van Lint C, et al. Human immunodeficiency virus type-1 Tat/co-activator acetyltransferase interactions inhibit p53Lys-320 acetylation and p53-responsive transcription. J Biol Chem. 2003;278:12310–8.PubMedCrossRef

39.

De Falco G, Bellan C, Lazzi S, et al. Interaction between HIV-1 Tat and pRb2/p130: a possible mechanism in the pathogenesis of AIDS-related neoplasms. Oncogene. 2003;22:6214–9.PubMedCrossRef

40.

Wright S, Lu X, Peterlin BM. Human immunodeficiency virus type 1 tat directs transcription through attenuation sites within the mouse c-myc gene. J Mol Biol. 1994;243:568–73.PubMedCrossRef

41.

Campioni D, Corallini A, Zauli G, et al. HIV type 1 extracellular Tat protein stimulates growth and protects cells of BK virus/tat transgenic mice from apoptosis. AIDS Res Hum Retroviruses. 1995;11:1039–48.PubMedCrossRef

42.

Colombrino E, Rossi E, Ballon G, et al. Human immunodeficiency virus type 1 Tat protein modulates cell cycle and apoptosis in Epstein-Barr virus-immortalized B cells. Exp Cell Res. 2004;295:539–48.PubMedCrossRef

43.

Nyagol J, Leucci E, Onnis A, et al. The effects of HIV-1 Tat protein on cell cycle during cervical carcinogenesis. Cancer Biol Ther. 2006;5:684–90.PubMedCrossRef

44.

Altavilla G, Caputo A, Lanfredi M, et al. Enhancement of chemical hepatocarcinogenesis by the HIV-1 tat gene. Am J Pathol. 2000;157:1081–9.PubMedCrossRef

45.

Corallini A, Campioni D, Rossi C, et al. Promotion of tumour metastases and induction of angiogenesis by native HIV-1 Tat protein from BK virus/tat transgenic mice. AIDS. 1996;10:701–10.PubMedCrossRef

46.

Wistuba II, Behrens C, Milchgrub S, et al. Comparison of molecular changes in lung cancers in HIV-positive and HIV-indeterminate subjects. JAMA. 1998;279:1554–9.PubMedCrossRef

47.

Puoti M, Bruno R, Soriano V, et al. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS. 2004;18:2285–93.PubMedCrossRef

48.

McGinnis KA, Fultz SL, Skanderson M, et al. Hepatocellular carcinoma and non-Hodgkin’s lymphoma: the roles of HIV, hepatitis C infection, and alcohol abuse. J Clin Oncol. 2006;24:5005–9.PubMedCrossRef

49.

Palefsky J. Human papillomavirus-related disease in people with HIV. Curr Opin HIV AIDS. 2009;4:52–6.PubMedCrossRef

50.

Marur S, D’Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 2010;11:781–9.PubMedCrossRef

51.

Ahdieh L, Munoz A, Vlahov D, et al. Cervical neoplasia and repeated positivity of human papillomavirus infection in human immunodeficiency virus-seropositive and -seronegative women. Am J Epidemiol. 2000;151:1148–57.PubMedCrossRef

52.

Kato T, Koriyama C, Khan N, et al. EGFR mutations and human papillomavirus in lung cancer. Lung Cancer. 2012;78:144–7.PubMedCrossRef

53.

Syrjanen K. Detection of human papillomavirus in lung cancer: systematic review and meta-analysis. Anticancer Res. 2012;32:3235–50.PubMed

54.

Thompson LD, Fisher SI, Chu WS, et al. HIV-associated Hodgkin lymphoma: a clinicopathologic and immunophenotypic study of 45 cases. Am J Clin Pathol. 2004;121:727–38.PubMedCrossRef

55.

Carbone A, Gloghini A, Serraino D, Spina M. HIV-associated Hodgkin lymphoma. Curr Opin HIV AIDS. 2009;4:3–10.PubMedCrossRef

56.

Wieland U, Kreuter A. Merkel cell polyomavirus infection and Merkel cell carcinoma in HIV-positive individuals. Curr Opin Oncol. 2011;23:488–93.PubMedCrossRef

57.

Douek DC. Disrupting T-cell homeostasis: how HIV-1 infection causes disease. AIDS Rev. 2003;5:172–7.PubMed

58.

Sousa AE, Carneiro J, Meier-Schellersheim M, et al. CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J Immunol. 2002;169:3400–6.PubMed

59.

Schacker TW, Nguyen PL, Martinez E, et al. Persistent abnormalities in lymphoid tissues of human immunodeficiency virus-infected patients successfully treated with highly active antiretroviral therapy. J Infect Dis. 2002;186:1092–7.PubMedCrossRef

60.

Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370:59–67.PubMedCrossRef

61.

Plaeger SF, Collins BS, Musib R, et al. Immune activation in the pathogenesis of treated chronic HIV disease: a workshop summary. AIDS Res Hum Retroviruses. 2012;28:469–77.PubMed

62.

Pine SR, Mechanic LE, Enewold L, et al. Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst. 2011;103:1112–22.PubMedCrossRef

63.

Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5:e203.PubMedCrossRef

64.

Kalayjian RC, Machekano RN, Rizk N, et al. Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy. J Infect Dis. 2010;201:1796–805.PubMedCrossRef

65.

Lifson AR, Lando HA. Smoking and HIV: prevalence, health risks, and cessation strategies. Curr HIV/AIDS Rep. 2012;9:223–30.PubMedCrossRef

66.

Lifson AR, Neuhaus J, Arribas JR, et al. Smoking-related health risks among persons with HIV in the Strategies for Management of Antiretroviral Therapy clinical trial. Am J Public Health. 2010;100:1896–903.PubMedCrossRef

67.

Engels EA, Brock MV, Chen J, et al. Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol. 2006;24:1383–8.PubMedCrossRef

68.

Kirk GD, Merlo C, O’ Driscoll P, et al. HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis. 2007;45:103–10.PubMedCrossRef

69.

Olivero OA, Tejera AM, Fernandez JJ, et al. Zidovudine induces S-phase arrest and cell cycle gene expression changes in human cells. Mutagenesis. 2005;20:139–46.PubMedCrossRef

70.

Carter MM, Torres SM, Cook Jr DL, et al. Relative mutagenic potencies of several nucleoside analogs, alone or in drug pairs, at the HPRT and TK loci of human TK6 lymphoblastoid cells. Environ Mol Mutagen. 2007;48:239–47.PubMedCrossRef

71.

Crum-Cianflone NF, Hullsiek KH, Marconi V, et al. The impact of nelfinavir exposure on cancer development among a large cohort of HIV-infected patients. J Acquir Immune Defic Syndr. 2009;51:305–9.PubMedCrossRef

72.

Yopp AC, Subramanian M, Jain MK, et al. Presentation, treatment, and clinical outcomes of patients with hepatocellular carcinoma, with and without human immunodeficiency virus infection. Clin Gastroenterol Hepatol. 2012;10:1284–90.PubMedCrossRef

73.

Wilkins K, Turner R, Dolev JC, et al. Cutaneous malignancy and human immunodeficiency virus disease. J Am Acad Dermatol. 2006;54:189–206. quiz 207–110.PubMedCrossRef

74.

Nguyen P, Vin-Christian K, Ming ME, Berger T. Aggressive squamous cell carcinomas in persons infected with the human immunodeficiency virus. Arch Dermatol. 2002;138:758–63.PubMedCrossRef

75.

• Sigel K, Wisnivesky J, Gordon K, et al. HIV as an independent risk factor for incident lung cancer. AIDS. 2012;26:1017–25. This Veterans Aging Cohort Study compared lung cancer incidence in demographically similar HIV-infected and uninfected veterans. After controlling for smoking, HIV remained an independent risk factor for lung cancer in one of the largest studies to directly examine the contributions of HIV and smoking to lung cancer risk.PubMedCrossRef

76.

D’Jaen GA, Pantanowitz L, Bower M, et al. Human immunodeficiency virus-associated primary lung cancer in the era of highly active antiretroviral therapy: a multi-institutional collaboration. Clin Lung Cancer. 2010;11:396–404.PubMedCrossRef

77.

Gewurz BE, Dezube BJ, Pantanowitz L. HIV and the breast. AIDS Read. 2005;15(392–396):399–402.

78.

Chapman C, Aboulafia DM, Dezube BJ, Pantanowitz L. Human immunodeficiency virus-associated adenocarcinoma of the colon: clinicopathologic findings and outcome. Clin Colorectal Cancer. 2009;8:215–9.PubMedCrossRef

79.

Biggar RJ, Engels EA, Ly S, et al. Survival after cancer diagnosis in persons with AIDS. J Acquir Immune Defic Syndr. 2005;39:293–9.PubMedCrossRef

80.

Shiels MS, Cole SR, Mehta SH, Kirk GD. Lung cancer incidence and mortality among HIV-infected and HIV-uninfected injection drug users. J Acquir Immune Defic Syndr. 2010;55:510–5.PubMedCrossRef

81.

• Montoto S, Shaw K, Okosun J, et al. HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. J Clin Oncol. 2012;30:4111–6. This trial reported on 93 HIV-infected and 131 HIV-uninfected patients with HL treated with aggressive combination chemotherapy from 1997 to 2010. Despite more extensive disease and adverse prognostic factors, HIV-infected patients had similar five-year overall and event-free survival to HIV-negative patients.PubMedCrossRef

82.

Abramowitz L, Mathieu N, Roudot-Thoraval F, et al. Epidermoid anal cancer prognosis comparison among HIV + and HIV- patients. Aliment Pharmacol Ther. 2009;30:414–21.PubMedCrossRef

83.

Lim C, Goutte N, Gervais A, et al. Standardized care management ensures similar survival rates in HIV-positive and HIV-negative patients with hepatocellular carcinoma. J Acquir Immune Defic Syndr. 2012;61:581–7.PubMedCrossRef

84.

Powles T, Thirwell C, Newsom-Davis T, et al. Does HIV adversely influence the outcome in advanced non-small-cell lung cancer in the era of HAART? Br J Cancer. 2003;89:457–9.PubMedCrossRef

85.

Powles T, Imami N, Nelson M, et al. Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma. AIDS. 2002;16:531–6.PubMedCrossRef

86.

Deeken JF, Pantanowitz L, Dezube BJ. Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook. Curr Opin Oncol. 2009;21:445–54.PubMedCrossRef

87.

Persad GC, Little RF, Grady C. Including persons with HIV infection in cancer clinical trials. J Clin Oncol. 2008;26:1027–32.PubMedCrossRef

88.

European AIDS Clinical Society: Cancer Screening Methods. Available at http://www.europeanaidsclinicalsociety.org/Guidelines/G2_p37.htm. Accessed March 2013.

89.

New York State Health Department: Adult HIV Clinical Guidelines. Available at http://www.hivguidelines.org/clinical-guidelines/adults. Accessed March 2013.

90.

• Sigel K, Dubrow R, Silverberg M, et al. Cancer screening in patients infected with HIV. Curr HIV/AIDS Rep. 2011;8:142–52. This recent article reviews existing evidence for cancer screening in HIV-infected patients. A paradigm for approaches to cancer screening is proposed and key research questions are identified, including the need for HIV-specific cancer screening guidelines.PubMedCrossRef

91.

Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395–409.PubMedCrossRef

92.

Goldie SJ, Kuntz KM, Weinstein MC, et al. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. JAMA. 1999;281:1822–9.PubMedCrossRef

93.

Lam JM, Hoch JS, Tinmouth J, et al. Cost-effectiveness of screening for anal precancers in HIV-positive men. AIDS. 2011;25:635–42.PubMedCrossRef

94.

Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. MMWR 2009; 58:68–91.

95.

Reinhold JP, Moon M, Tenner CT, et al. Colorectal cancer screening in HIV-infected patients 50 years of age and older: missed opportunities for prevention. Am J Gastroenterol. 2005;100:1805–12.PubMedCrossRef

96.

• Helleberg M, Afzal S, Kronborg G, et al. Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study. Clin Infect Dis. 2013;56:727–34. This study using the Danish nationwide HIV cohort and matched HIV-negative controls estimated mortality rates and population-attributable risk of death associated with smoking. The results suggested that HIV-infected smokers on HAART lose more life-years from smoking than HIV and have twice the population-attributable risk of death associated with smoking compared to controls.PubMedCrossRef

97.

Recommended adult immunization schedule: United States, 2012. Ann Intern Med. 2012; 156:211–217.

98.

Drechsler H, Zhang S, Maalouf N, et al. Impact of Statin Exposure on Mortality and Non-AIDS Complications in HIV Patients on HAART. [abstract R-260]. Presented at the 20th Conference for Retroviruses and Opportunistic Infections. Atlanta, GA; March 3–6, 2013.

99.

Overton ET, Kitch D, Benson CA, et al. Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death. Clin Infect Dis. 2013. doi:10.1093/cid/cit053.

Titel: Non-AIDS-defining Cancers Among HIV-Infected Patients
verfasst von: James Cutrell
Roger Bedimo
Publikationsdatum: 01.09.2013
Verlag: Springer US
Erschienen in: Current HIV/AIDS Reports / Ausgabe 3/2013
Print ISSN: 1548-3568
Elektronische ISSN: 1548-3576
DOI: https://doi.org/10.1007/s11904-013-0166-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2013

Oral Health Considerations in HIV-Infected Children

HIV and Neurocognitive Dysfunction

Combination HIV Prevention: The Value and Interpretation of Mathematical Models

Transmission of Tuberculosis in Resource-Limited Settings

Update on HIV/HCV Coinfection